Trump Card: Trump Entertainment (TRMP)
Cramer notes that TRMP is up a "cool 30%" from where he recommended it last year and suggests that it is good for a trade or a buy, but only before November 14 when the company is going to seek approval from the Philadelphia Gaming board to open a casino in the city. If the deal goes through, TRMP should jump $4. Cramer praised the company for remodeling its casinos: "Renovations are beginning to attract high-quality players," and commented on the stock's recent "upside surprise." Cramer has faith that CEO Jim Perry will continue to make improvements in Trump casinos in Atlantic City, which was once a "dingy environment," and predicts that the stock could reach $32 from $22.05. He would only buy TRMP at a low price.
Cramer notes that while some stocks "lanugish" in a portfolio, others can yield a 50% profit, and he identifies Mastercard as the latter type company. Like Microsoft, MA is worth buying even though it is high, and Cramer identifies RIMM, CSCO, NYX as other stocks that can be picked up even after a good run. In spite of the fact that those who buy MA now have missed "40 odd points," the company has a large upside potential and the IPO was underpriced. In addition, Cramer calls Mastercard an "irreplaceable franchise," with growth potential in China and incredible earnings power. Although MA has already had two large upside surprises, Cramer predicts it will climb steadily from $89.20 to $150.
Related: Abbi Adest discusses the sharp decline in consumer credit.
For the coming week, Cramer would buy SPLS and TGT, noting that investment wizard, Warren Buffet, has been picking up Target. Instead of GPS, Cramer likes MW and TWB. He predicts that MRVL will give a bad report next week but that it will announce good year-over-year numbers. Finally, Cramer notes the panic-selling in drug stocks due to worries over price controls, and suggests that investors "wait for the institutions to finish selling ... and when the stocks open up and go up for the rest of the day, you will know all the inventory has been cleaned out."
Related: Shlomi Cohen discusses a potential leveraged buyout of MRVL in the wake of its options-backdating scandal.
CEO Interview: Jonah Shacknai or Medicis Pharmaceuticals (MRX):
Jonah Shacknai discussed three acne drugs produced by MRX. First, he notes that the "market is loving" Solodyn, the first antibiotic to appear on the market for moderate-to-severe acne. He also thinks that Ziana, which was approved by the FDA last week, will be a "blockbuster" and says that Prolane waiting for the green light. Cramer called MRX "a bull story between now and the end of the year."
Related: Jonah Shacknai was also a guest on Jim Cramer's September 13th show when he discussed MRX's anti-wrinkle treatment, Restylane.
More: Cramer's latest stock picks, including: Mad Money Recap, Lightening Round, Stop Trading and his Radio Show.
Get Cramer's Picks by email -- it's free and takes only a few seconds to sign up.
Seeking Alpha is not affiliated with CNBC, Jim Cramer or TheStreet.com